Immunohistological analysis of B7-H4, IDO1, and PD-L1 expression and tumor immune microenvironment based on triple-negative breast cancer subtypes

被引：0
|
作者：
Fumiaki Sanuki
Yuka Mikami
Hirotake Nishimura
Yoshinori Fujita
Yasumasa Monobe
Tsunehisa Nomura
Naruto Taira
Takuya Moriya
机构：
[1] Kawasaki Medical School,Department of Pathology
[2] Kawasaki Medical School General Medical Center,Department of Pathology
[3] Kawasaki Medical School,Department of Breast and Thyroid Surgery
来源：
Breast Cancer | 2023年 / 30卷
关键词：
Breast cancer; Triple-negative breast cancer; Immune checkpoint molecules; Immune checkpoint inhibitors; Tumor-infiltrating lymphocytes;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1041 / 1053
页数：12
相关论文
共 50 条
  • [31] Correlation analysis of DLG5 and PD-L1 expression in triple-negative breast cancer
    Che, Jingmin
    Chen, Bo
    Wang, Xusheng
    Liu, Baoe
    Xu, Cuixiang
    Wang, Huxia
    Sun, Jingying
    Feng, Qing
    Zhao, Xiangrong
    Song, Zhangjun
    BMC CANCER, 2025, 25 (01)
  • [32] Spatial Profile of Tumor Microenvironment in PD-L1-Negative and PD-L1-Positive Triple-Negative Breast Cancer
    Tashireva, Liubov A.
    Kalinchuk, Anna Yu.
    Gerashchenko, Tatiana S.
    Menyailo, Maksim
    Khozyainova, Anna
    Denisov, Evgeniy V.
    Perelmuter, Vladimir M.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (02)
  • [33] Progress of PD-1/PD-L1 immune checkpoint inhibitors in the treatment of triple-negative breast cancer
    Hongshu Li
    Ying Chang
    Tiefeng Jin
    Meihua Zhang
    Cancer Cell International, 25 (1)
  • [34] PD-L1 expression of tumor infiltrating immune cells has potential as a biomarker in triple-negative breast cancers
    Harada, Yurina
    Kubo, Makoto
    Mori, Hitomi
    Kai, Masaya
    Yamada, Mai
    Kurata, Kanako
    Kawaji, Hitomi
    Kaneshiro, Kazuhisa
    Hayashi, Saori
    Shimazaki, Akiko
    Morisaki, Takafumi
    Yamaguchi, Rin
    Arima, Nobuyuki
    Nishimura, Reiki
    Okido, Masayuki
    Nakamura, Masafumi
    CANCER RESEARCH, 2020, 80 (04)
  • [35] JAK2 and PD-L1 Amplification Enhance the Dynamic Expression of PD-L1 in Triple-negative Breast Cancer
    Chen, Meixuan
    Pockaj, Barbara
    Andreozzi, Mariacarla
    Barrett, Michael T.
    Krishna, Sri
    Eaton, Seron
    Niu, Ruifang
    Anderson, Karen S.
    CLINICAL BREAST CANCER, 2018, 18 (05) : E1205 - E1215
  • [36] Combined immunotherapy for metastatic triple-negative breast cancer based on PD-1/PD-L1 immune checkpoint blocking
    He, Rui
    Yuan, Xing
    Chen, Zeran
    Zheng, Yongfeng
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2022, 113
  • [37] The Expression of PD-L1 and B7-H4 in Thymic Epithelial Tumor and Its Relationship With Tumor Immune-Infiltrating Cells
    Yan, Xiaotian
    Feng, Jie
    Hong, Bo
    Qian, Yun
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [38] The prognostic value of PD-L1/PD-1 expression and PD-L1 gene copy number on/in tumor and immune cells in triple negative breast cancer
    Seitz, S.
    Brockhoff, G.
    Weber, F.
    Klinkhammer-Schalke, M.
    Zeman, F.
    Ugocsai, P.
    Ortmann, O.
    Wege, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 4 - 4
  • [39] MUC1-C Induces PD-L1 and Immune Evasion in Triple-Negative Breast Cancer
    Maeda, Takahiro
    Hiraki, Masayuki
    Jin, Caining
    Rajabi, Hasan
    Tagde, Ashujit
    Alam, Maroof
    Bouillez, Audrey
    Hu, Xiufeng
    Suzuki, Yozo
    Miyo, Masaaki
    Hata, Tsuyoshi
    Hinohara, Kunihiko
    Kufe, Donald
    CANCER RESEARCH, 2018, 78 (01) : 205 - 215
  • [40] PD-L1: an unavoidable biomarker in advanced triple-negative breast cancer
    Akiki, Mira
    Haddad, Fady Gh
    Kourie, Hampig Raphael
    Khaddage, Abir
    Smayra, Viviane Track
    BIOMARKERS IN MEDICINE, 2019, 13 (18) : 1539 - 1541
12345